{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:36:05Z","timestamp":1788428165476,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s00105-009-1825-y","type":"journal-article","created":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T20:56:53Z","timestamp":1259701013000},"page":"999-1009","source":"Crossref","is-referenced-by-count":21,"title":["Rosazea 2009","Rosacea 2009"],"prefix":"10.1007","volume":"60","author":[{"given":"A.","family":"Sobottka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,3]]},"reference":[{"key":"1825_CR1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000136656","volume":"217","author":"Schaefer","year":"2008","unstructured":"Schaefer I et al (2008) Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 217(2):169\u2013172","journal-title":"Dermatology"},{"key":"1825_CR2","first-page":"419","volume":"69","author":"Berg","year":"1989","unstructured":"Berg M, Liden S (1989) An epidemiological study of rosacea. Acta Derm Venereol 69(5):419\u2013423","journal-title":"Acta Derm Venereol"},{"key":"1825_CR3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1600-0781.2006.00220.x","volume":"22","author":"Yazici","year":"2006","unstructured":"Yazici AC et al (2006) GSTM1 and GSTT1 null genotypes as possible heritable factors of rosacea. Photodermatol Photoimmunol Photomed 22(4):208\u2013210","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"1825_CR4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/archderm.1994.01690030091015","volume":"130","author":"Wilkin","year":"1994","unstructured":"Wilkin JK (1994) Rosacea. Pathophysiology and treatment. Arch Dermatol 130(3):359\u2013362","journal-title":"Arch Dermatol"},{"key":"1825_CR5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00105-005-1009-3","volume":"56","author":"Lehmann","year":"2005","unstructured":"Lehmann P (2005) Rosazea: Epidemiologie, Pathogenese, Klinik und Therapie. Hautarzt 56(9):871\u2013885","journal-title":"Hautarzt"},{"key":"1825_CR6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF00424276","volume":"281","author":"Brinnel","year":"1989","unstructured":"Brinnel H et al (1989) Rosacea: disturbed defense against brain overheating. Arch Dermatol Res 281(1):66\u201372","journal-title":"Arch Dermatol Res"},{"key":"1825_CR7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0306-9877(98)90019-6","volume":"50","author":"Nagasaka","year":"1998","unstructured":"Nagasaka T et al (1998) Selective brain cooling in hyperthermia: the mechanisms and medical implications. Med Hypotheses 50(3):203\u2013211","journal-title":"Med Hypotheses"},{"key":"1825_CR8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/bjo.2006.101121","volume":"91","author":"Smith","year":"2007","unstructured":"Smith JR et al (2007) Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol 91(2):226\u2013229","journal-title":"Br J Ophthalmol"},{"key":"1825_CR9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00403-007-0816-z","volume":"300","author":"Aroni","year":"2008","unstructured":"Aroni K et al (2008) A study of the pathogenesis of Rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res 300(3):125\u2013131","journal-title":"Arch Dermatol Res"},{"key":"1825_CR10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1600-0560.1998.tb01739.x","volume":"25","author":"Roihu","year":"1998","unstructured":"Roihu T, Kariniemi AL (1998) Demodex mites in acne rosacea. J Cutan Pathol 25(10):550\u2013552","journal-title":"J Cutan Pathol"},{"key":"1825_CR11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1365-2133.1993.tb00261.x","volume":"128","author":"Forton","year":"1993","unstructured":"Forton F, Seys B (1993) Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol 128(6):650\u2013659","journal-title":"Br J Dermatol"},{"key":"1825_CR12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2133.2007.08028.x","volume":"157","author":"Lacey","year":"2007","unstructured":"Lacey N et al (2007) Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol 157(3):474\u2013481","journal-title":"Br J Dermatol"},{"key":"1825_CR13","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","volume":"46","author":"Wilkin","year":"2002","unstructured":"Wilkin J et al (2002) Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 46(4):584\u2013587","journal-title":"J Am Acad Dermatol"},{"key":"1825_CR14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nm1616","volume":"13","author":"Yamasaki","year":"2007","unstructured":"Yamasaki K et al (2007) Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 13(8):975\u2013980","journal-title":"Nat Med"},{"key":"1825_CR15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2009.04.007","volume":"55","author":"Yamasaki","year":"2009","unstructured":"Yamasaki K, Gallo RL (2009) The molecular pathology of rosacea. J Dermatol Sci 55(2):77\u201381","journal-title":"J Dermatol Sci"},{"key":"1825_CR16","first-page":"371","volume":"65","author":"Salamon","year":"2008","unstructured":"Salamon M et al (2008) Concentration of selected cytokines in serum of patients with acne rosacea. Przegl Lek 65(9):371\u2013374","journal-title":"Przegl Lek"},{"key":"1825_CR17","first-page":"17","volume":"74","author":"Jones","year":"2004","unstructured":"Jones D (2004) Reactive oxygen species and rosacea. Cutis 74 (Suppl 3):17\u201320, 32\u201334","journal-title":"Cutis"},{"key":"1825_CR18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF02850193","volume":"18","author":"Miyachi","year":"2001","unstructured":"Miyachi Y (2001) Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Adv Ther 18(6):237\u2013243","journal-title":"Adv Ther"},{"key":"1825_CR19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jaad.2008.10.014","volume":"60","author":"Tisma","year":"2009","unstructured":"Tisma VS et al (2009) Oxidative stress and ferritin expression in the skin of patients with rosacea. J Am Acad Dermatol 60(2):270\u2013276","journal-title":"J Am Acad Dermatol"},{"key":"1825_CR20","first-page":"A","volume":"104","author":"Lehmann","year":"2007","unstructured":"Lehmann P (2007) Rosazea: Epidemiologie, Pathogenese, Klinik und Therapie. Dtsch \u00c4rztebl 104(24):A-1741\/B-1536\/C-1475(104(24)","journal-title":"Dtsch \u00c4rztebl"},{"key":"1825_CR21","doi-asserted-by":"crossref","unstructured":"Lehmann P, Arens A (2000) Rosacea fulminans. In: Plettenberg A, Meigel WN, Moll I (Hrsg) Dermatologie an der Schwelle zum neuen Jahrtausend. Springer, Berlin Heidelberg New York Tokyo, S 257\u2013259","DOI":"10.1007\/978-3-642-57191-6_69"},{"key":"1825_CR22","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jaad.2004.01.048","volume":"50","author":"Wilkin","year":"2004","unstructured":"Wilkin J et al (2004) Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 50(6):907\u2013912","journal-title":"J Am Acad Dermatol"},{"key":"1825_CR23","doi-asserted-by":"crossref","unstructured":"Plewig GK, Kligman AM (2000) Acne and rosacea, Vol. 1, 3rd edn. Springer, Berlin Heidelberg New York Tokyo, p 744","DOI":"10.1007\/978-3-642-59715-2"},{"key":"1825_CR24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.sap.0000199155.73000.2f","volume":"56","author":"Payne","year":"2006","unstructured":"Payne WG et al (2006) Down-regulating causes of fibrosis with tamoxifen: a possible cellular\/molecular approach to treat rhinophyma. Ann Plast Surg 56(3):301\u2013305","journal-title":"Ann Plast Surg"},{"key":"1825_CR25","unstructured":"Powell F (2009) Rosacea \u2013 diagnosis and management, Vol. 1. Informa Healthcare USA, Inc., p\u00a0140"},{"key":"1825_CR26","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1365-2230.2008.02892.x","volume":"33","author":"Nagasaka","year":"2008","unstructured":"Nagasaka T et al (2008) Persistent lymphoedema in Morbihan disease: formation of perilymphatic epithelioid cell granulomas as a possible pathogenesis. Clin Exp Dermatol 33(6):764\u2013767","journal-title":"Clin Exp Dermatol"},{"key":"1825_CR27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/09546630801955176","volume":"19","author":"Jayawant","year":"2008","unstructured":"Jayawant SS et al (2008) Prescription refills and healthcare costs associated with topical metronidazole in Medicaid enrolled patients with rosacea. J Dermatolog Treat 19(5):267\u2013273","journal-title":"J Dermatolog Treat"},{"key":"1825_CR28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1468-3083.2008.02940.x","volume":"23","author":"Mostafa","year":"2009","unstructured":"Mostafa FF et al (2009) Comparative study of some treatment modalities of rosacea. J Eur Acad Dermatol Venereol 23(1):22\u201328","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1825_CR29","first-page":"541","volume":"7","author":"Thiboutot","year":"2008","unstructured":"Thiboutot DM et al (2008) Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol 7(6):541\u2013546","journal-title":"J Drugs Dermatol"},{"key":"1825_CR30","unstructured":"Lehmann P (2003) Klinische Studien zur topischen Therapie mit Metronidazol bei Rosazea. In: Sch\u00e4fer H (Hrsg) Rosazea-Klinik und aktuelle Therapie. Georg Thieme, Stuttgart, S 41\u201350"},{"key":"1825_CR31","first-page":"CD003262","volume":"2004","author":"van","year":"2004","unstructured":"van Zuuren EJ et al (2004) Interventions for rosacea. Cochrane Database Syst Rev 2004(1):CD003262","journal-title":"Cochrane Database Syst Rev"},{"key":"1825_CR32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-4632.2004.02130.x","volume":"44","author":"Altinyazar","year":"2005","unstructured":"Altinyazar HC et al (2005) Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol 44(3):252\u2013255","journal-title":"Int J Dermatol"},{"key":"1825_CR33","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/archderm.140.10.1282-b","volume":"140","author":"Czernielewski","year":"2004","unstructured":"Czernielewski J, Liu Y (2004) Comparison of 15% azelaic acid gel and 0.75% metronidazole gel for the topical treatment of papulopustular rosacea. Arch Dermatol 140(10):1282\u20131283; author reply 1283","journal-title":"Arch Dermatol"},{"key":"1825_CR34","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archderm.1987.01660290077020","volume":"123","author":"Bleicher","year":"1987","unstructured":"Bleicher PA, Charles JH, Sober AJ (1987) Topical metronidazole therapy for rosacea. Arch Dermatol 123(5):609\u2013614","journal-title":"Arch Dermatol"},{"key":"1825_CR35","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1540-9740.2005.03740.x","volume":"4","author":"Crawford","year":"2005","unstructured":"Crawford KM, Russ B, Bostrom P (2005) Pimecrolimus for treatment of acne rosacea. Skinmed 4(3):147\u2013150","journal-title":"Skinmed"},{"key":"1825_CR36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/00015550510043975","volume":"86","author":"Cunha","year":"2006","unstructured":"Cunha PR, Rossi AB (2006) Pimecrolimus cream 1% is effective in a case of granulomatous rosacea. Acta Derm Venereol 86(1):71\u201372","journal-title":"Acta Derm Venereol"},{"key":"1825_CR37","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ajo.2007.01.054","volume":"143","author":"Kheirkhah","year":"2007","unstructured":"Kheirkhah A et al (2007) Corneal manifestations of ocular demodex infestation. Am J Ophthalmol 143(5):743\u2013749","journal-title":"Am J Ophthalmol"},{"key":"1825_CR38","doi-asserted-by":"crossref","unstructured":"Sch\u00f6fer H (2003) Rosazea: Klinik und aktuelle Therapie. Georg Thieme, Stuttgart New York","DOI":"10.1055\/b-002-29659"},{"key":"1825_CR39","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1365-4632.2006.02944.x","volume":"45","author":"Sharquie","year":"2006","unstructured":"Sharquie KE, Najim RA, Al-Salman HN (2006) Oral zinc sulfate in the treatment of rosacea: a double-blind, placebo-controlled study. Int J Dermatol 45(7):857\u2013861","journal-title":"Int J Dermatol"},{"key":"1825_CR40","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archderm.134.7.884","volume":"134","author":"Erdogan","year":"1998","unstructured":"Erdogan FG et al (1998) Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol 134(7):884\u2013885","journal-title":"Arch Dermatol"},{"key":"1825_CR41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archderm.134.6.679","volume":"134","author":"Dahl","year":"1998","unstructured":"Dahl MV et al (1998) Topical metronidazole maintains remissions of rosacea. Arch Dermatol 134(6):679\u2013683","journal-title":"Arch Dermatol"},{"key":"1825_CR42","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2005.04.069","volume":"53","author":"Sanchez","year":"2005","unstructured":"Sanchez J et al (2005) A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol 53(5):791\u2013797","journal-title":"J Am Acad Dermatol"},{"key":"1825_CR43","first-page":"641","volume":"6","author":"Fowler","year":"2007","unstructured":"Fowler JF Jr (2007) Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol 6(6):641\u2013645","journal-title":"J Drugs Dermatol"},{"key":"1825_CR44","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1600-0625.2008.00716.x","volume":"17","author":"Bender","year":"2008","unstructured":"Bender A et al (2008) Tetracycline suppresses ATP gamma S-induced CXCL8 and CXCL1 production by the human dermal microvascular endothelial cell-1 (HMEC-1) cell line and primary human dermal microvascular endothelial cells. Exp Dermatol 17(9):752\u2013760","journal-title":"Exp Dermatol"},{"key":"1825_CR45","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","volume":"56","author":"Del","year":"2007","unstructured":"Del Rosso JQ et al (2007) Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 56(5):791\u2013802","journal-title":"J Am Acad Dermatol"},{"key":"1825_CR46","first-page":"573","volume":"7","author":"Del","year":"2008","unstructured":"Del Rosso JQ, Schlessinger J, Werschler P (2008) Comparison of anti-inflammatory dose doxycycline versus doxycycline 100\u00a0mg in the treatment of rosacea. J Drugs Dermatol 7(6):573\u2013576","journal-title":"J Drugs Dermatol"},{"key":"1825_CR47","first-page":"27","volume":"Today","author":"Berman","year":"2004","unstructured":"Berman B, Perez OA, Zell D (2004) Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today (Barc) 43(1):27\u201334","journal-title":"Drugs"},{"key":"1825_CR48","first-page":"19","volume":"75","author":"Berman","year":"2005","unstructured":"Berman B, Zell D (2005) Subantimicrobial dose doxycycline: a unique treatment for rosacea. Cutis 75 (Suppl 4):19\u201324","journal-title":"Cutis"},{"key":"1825_CR49","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1540-9740.2007.06460.x","volume":"6","author":"Theobald","year":"2007","unstructured":"Theobald K, Bradshaw M, Leyden J (2007) Anti-inflammatory dose doxycycline (40\u00a0mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. Skinmed 6(5):221\u2013226","journal-title":"Skinmed"},{"key":"1825_CR50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12019-007-8003-x","volume":"33","author":"Wise","year":"2007","unstructured":"Wise RD (2007) Submicrobial doxycycline and rosacea. Compr Ther 33(2):78\u201381","journal-title":"Compr Ther"},{"key":"1825_CR51","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1468-3083.2009.03132.x","volume":"23","author":"Bakar","year":"2009","unstructured":"Bakar O et al (2009) Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. J Eur Acad Dermatol Venereol 23(5):544\u2013549","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1825_CR52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2230.2006.02322.x","volume":"32","author":"Bakar","year":"2007","unstructured":"Bakar O et al (2007) The effect of azithromycin on reactive oxygen species in rosacea. Clin Exp Dermatol 32(2):197\u2013200","journal-title":"Clin Exp Dermatol"},{"key":"1825_CR53","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00417-005-0212-3","volume":"244","author":"Maatta","year":"2006","unstructured":"Maatta M et al (2006) Tear fluid levels of MMP-8 are elevated in ocular rosacea--treatment effect of oral doxycycline. Graefes Arch Clin Exp Ophthalmol 244(8):957\u2013962","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1825_CR54","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/lsm.20621","volume":"40","author":"Bernstein","year":"2008","unstructured":"Bernstein EF, Kligman A (2008) Rosacea treatment using the new-generation, high-energy, 595\u00a0nm, long pulse-duration pulsed-dye laser. Lasers Surg Med 40(4):233\u2013239","journal-title":"Lasers Surg Med"},{"key":"1825_CR55","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/09546630802512653","volume":"20","author":"Cravo","year":"2009","unstructured":"Cravo M et al (2009) Combined carbon dioxide laser and bipolar electrocoagulation: another option to treat rhinophyma. J Dermatolog Treat 20(3):146\u2013148","journal-title":"J Dermatolog Treat"},{"key":"1825_CR56","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1468-3083.2007.02219.x","volume":"21","author":"Bryld","year":"2007","unstructured":"Bryld LE, Jemec GB (2007) Photodynamic therapy in a series of rosacea patients. J Eur Acad Dermatol Venereol 21(9):1199\u20131202","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1825_CR57","first-page":"6","volume":"5","author":"Katz","year":"2006","unstructured":"Katz B, Patel V (2006) Photodynamic therapy for the treatment of erythema, papules, pustules, and severe flushing consistent with rosacea. J Drugs Dermatol 5 (Suppl 2):6\u20138","journal-title":"J Drugs Dermatol"},{"key":"1825_CR58","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1524-4725.2009.01156.x","volume":"35","author":"Neuhaus","year":"2009","unstructured":"Neuhaus IM, Zane LT, Tope WD (2009) Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatol Surg 35(6):920\u2013928","journal-title":"Dermatol Surg"},{"key":"1825_CR59","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1365-2133.2008.08702.x","volume":"159","author":"Papageorgiou","year":"2008","unstructured":"Papageorgiou P et al (2008) Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol 159(3):628\u2013632","journal-title":"Br J Dermatol"},{"key":"1825_CR60","first-page":"385","volume":"65","author":"Salamon","year":"2008","unstructured":"Salamon M et al (2008) Quality of life in patients with rosacea. Przegl Lek 65(9):385\u2013389","journal-title":"Przegl Lek"},{"key":"1825_CR61","first-page":"997","volume":"64","author":"Chodkiewicz","year":"2007","unstructured":"Chodkiewicz J et al (2007) Psychosocial impact of rosacea. Przegl Lek 64(12):997\u20131001","journal-title":"Przegl Lek"},{"key":"1825_CR62","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1365-2133.2005.06895.x","volume":"153","author":"Gupta","year":"2005","unstructured":"Gupta MA et al (2005) Comorbidity of rosacea and depression: an analysis of the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey \u2013 Outpatient Department Data collected by the U.S. National Center for Health Statistics from 1995 to 2002. Br J Dermatol 153(6):1176\u20131181","journal-title":"Br J Dermatol"},{"key":"1825_CR63","unstructured":"Gollnick H et al (2009) Therapie der Rosazea mit Isotretinoin. Eine Multicenter Studie. JDDG (in press)"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-009-1825-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-009-1825-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-009-1825-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T23:09:30Z","timestamp":1710716970000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-009-1825-y"}},"subtitle":["Neue Erkenntnisse zur Pathophysiologie, klinische Manifestationsformen und Therapiestrategien","New advances in pathophysiology, clinical staging and therapeutic strategies"],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1825"],"URL":"https:\/\/doi.org\/10.1007\/s00105-009-1825-y","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}